الفهرس | Only 14 pages are availabe for public view |
Abstract Cancer during gestation is of great concern because it impacts lives of fetus and mother. Despite being rare during pregnancy, cancer is the 2nd cause of mortality among female patients in reproductive period. Pregnancy-associated malignancy is generally defined as a diagnosis during pregnancy or up to one year after delivery. Some studies also include cancers diagnosed prior to pregnancy. Signs and symptoms frequently seen in malignancy might overlap or masked by presence of pregnancy. Consequently, medical staff may easily attribute symptoms of an undiagnosed malignancy to pregnancy itself. Furthermore, concerns about fetal exposure to inherent risks of complementary examination, including irradiation, contrasts and operative/anesthetic techniques, might make doctors less prone to immediately investigate such symptoms (Andersson et al., 2015) This retrospective study will include all patients diagnosed with cancer during gestation at Mansoura University Hospitals, Egypt, including the departments of obstetrics and gynecology, clinical oncology and medical oncology over a 5 years period (January 2013– December 2018) These data was analysed : (Type of cancer, Maternal age at presentation, Stage of cancer, Gestational age at presentation, Treatment protocols, Fetal and neonatal outcome, Pregnancy complication, Maternal morbidity, Maternal mortality and Any related other data) there is statistically significant relation between outcome and cancer types. Among patients with breast cancer, 91.1% had good outcome. About 73%, 75% and 40% of patients with acute leukemia, lymphoma and malignancy without specific site respectively had good outcome. |